Form 4: Syndax Pharmaceuticals Executive Neil Gallagher Acquires Shares and Stock Options

Neil Gallagher, President and Head of R&D at Syndax Pharmaceuticals, acquired shares and stock options in the company on February 5, 2025.

Summary

• On February 5, 2025, Neil Gallagher, President and Head of R&D at Syndax Pharmaceuticals, acquired 18,500 shares of common stock through restricted stock units (RSUs) and an additional 23,400 shares of common stock through performance-based RSUs.
• Gallagher also acquired 110,500 stock options with an exercise price of $14.65, vesting monthly over four years.
• Following these transactions, Gallagher directly owns 89,713 shares of Syndax Pharmaceuticals common stock and 110,500 stock options.
• The RSUs vest over three years, with one-third vesting annually, contingent upon continued service.
• The number of shares acquired upon vesting of the performance-based RSUs is contingent upon the achievement of pre-established performance metrics.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects an executive increasing their stake in the company, suggesting confidence. However, it's a routine filing, so the impact is limited.

Positives

• The acquisition of shares and stock options by a key executive like Neil Gallagher can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for the RSUs and stock options incentivize continued service and commitment from the executive.

Future Outlook

The vesting of RSUs and stock options is contingent upon continued service and, in the case of performance-based RSUs, the achievement of pre-established performance metrics, suggesting a focus on long-term performance and alignment of executive incentives with company goals.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's prospects. Acquisitions of shares by executives are generally viewed positively.

Stakeholder Impact

• The acquisition of shares by an executive could positively influence shareholder sentiment.
• The vesting schedules incentivize the executive to contribute to the company's success, potentially benefiting employees and other stakeholders.

Key Dates

Keywords

Syndax Pharmaceuticals, Neil Gallagher, stock options, RSUs, Form 4, insider trading, executive compensation, beneficial ownership